HotSpot Therapeutics

HotSpot Therapeutics, founded in 2017 and based in Boston, is a private, preclinical-stage biotech developing a new class of allosteric drugs. The company's proprietary Smart Allostery™ platform integrates structural biology, pharmacology, chemistry, and AI to systematically drug natural regulatory hotspots on proteins. This approach aims to create highly selective and potentially safer therapeutics for challenging targets in oncology and autoimmunity, representing a significant departure from traditional drug discovery paradigms.

Smart Allostery™ platform integrating structure-function analysis, pharmacology, tailored chemistry, and AI to systematically discover and drug natural allosteric hotspots on proteins.

HotSpot operates in the competitive field of allosteric drug discovery, facing competition from both large pharmaceutical companies with internal efforts and other biotech platforms. Its differentiation lies in the systematic, AI-integrated approach to finding 'natural' regulatory hotspots, as opposed to discovering allosteric sites more serendipitously.